Generic, branded and biosimilar drugmaker Actavis (ACT) may be well-known among investors as a company that has used large acquisitions as one method to boost its earnings and sales sharply. Yet less attention perhaps has been paid to its savvy financial management. On June 10, the firm announced $3.7 billion in fresh financing at interest rates that undercut the rate it was paying for debt tied to its acquisition of Warner Chilcott.